Marine antitumor drugs: Status, shortfalls and strategies

Marine Drugs

Volumn 8, Issue 10, 2010, Pages 2702-2720

  Bhatnagar, Ira ^a   Kim, Se Kwon ^a  

^a Pukyong National University   (South Korea)

Author keywords

Cancer signaling pathways; Clinical status of antitumor drugs; Marine antitumor compounds; Shortfalls in cancer research

Indexed keywords

3 BENZYLIDENE 6 [(5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE] 2,5 PIPERAZINEDIONE; ANTINEOPLASTIC AGENT; ARENAMIDE A; ARENAMIDE B; BYROSTATIN 1; CRYPTO 52; CRYPTOPHYCIN 52; CYTARABINE; DEHYDRODIDEMNIN B; ERBULIN MESYLATE; ERIBULIN; FIJIOLIDE A; FUROSPONGOLIDE; LAURENDITERPENOL; LYS 355703; MAKALUVAMINE A; MARINE ANTINEOPLASTIC AGENT; MARIZOMIB; NATURAL PRODUCT; PLINABULIN; ROMIDEPSIN; SALINOSPORAMIDE A; SOBLIDOTIN; SQUALAMINE LACTATE; SULFATED SEPIELLA MAINDRONI INK POLYSACCHARIDE; TRABECTEDIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; MARINE SPECIES; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 78049428148     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md8102702     Document Type: Review

References (88)

1. da Rocha, A.B.; Lopes, R.M.; Schwartsmann, G. Natural products in anticancer therapy. Curr. Opin. Pharmacol. 2001, 1, 364-369.
2. McCullagh, M. Natural product pharmaceuticals-the third generation. Drug Disc. World 2008. Available online: http://www.ddw-online.com/drug-discovery/ 258437/natural-product-pharmaceuticals-the-third-generation.html (accessed on 25 August 2009).
3. Pallela, R.; Yoon, N.-Y.; Kim, S.K. Anti-photoaging and photoprotective compounds derived from marine organisms. Mar. Drugs 2010, 8, 1189-1202.
4. Mayer, A.M.; Rodríguez, A.D.; Berlinck, R.G.; Hamann, M.T. Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 2009, 1790, 283-308.
5. Hickford, S.J.; Blunt, J.W.; Munro, M.H. Antitumour polyether macrolides: Four new halichondrins from the New Zealand deep-water marine sponge Lissodendoryx sp. Bioorg. Med. Chem. 2009, 17, 2199-2203.
6. Aoki, S.; Cao, L.; Matsui, K.; Rachmat, R.; Akiyama, S.-i.; Kobayashi, M. Kendarimide A, a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp. Tetrahedron 2004, 60, 7053-7059.
7. Thomas, T.R.A.; Kavlekar, D.P.; LokaBharathi, P.A. Marine Drugs from Sponge-Microbe Association - A Review. Mar. Drugs 2010, 8, 1417-1468
8. Rodriguez, A.D.; Martinez, N. Marine antitumor agents: 14-deoxycrassin and pseudoplexaurol, new cembranoid diterpenes from the Caribbean gorgonian Pseudoplexaura porosa. Experientia 1993, 49, 179-181.
9. Olano, C.; Méndez, C.; Salas, J.A. Antitumor Compounds from Marine Actinomycetes. Mar. Drugs 2009, 7, 210-248.
10. Hassan, H.M.; Khanfar, M.A.; Elnagar, A.Y.; Mohammed, R.; Shaala, L.A.; Youssef, D.T.; Hifnawy, M.S.; El Sayed, K.A. Pachycladins A-E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados. J. Nat. Prod. 2010, 73, 848-853.
11. Maloney, K.N.; Macmillan, J.B.; Kauffman, C.A.; Jensen, P.R.; Dipasquale, A.G.; Rheingold, A.L.; Fenical, W. Lodopyridone, a structurally unprecedented alkaloid from a marine actinomycete. Org. Lett. 2009, 11, 5422-5424.
12. Tapiolas, D.M.; Roman, M.; Fenical, W.; Stout, T.J.; Clardy, J. Octalactins A and B: cytotoxic eight-membered-ring lactones from a marine bacterium, Streptomyces sp. J. Am. Chem. Soc. 1991, 113, 4682-4683.
13. Gorajana, A.;Venkatesan, M.; Vinjamuri, S.; Kurada, V.V.S.N.B.; Peela, S.; Jangam, P.; Poluri, E.; Zeeck, A. Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7. Microbiol. Res. 2007, 162, 322-327.
14. Du, L.; Zhu, T.; Fang, Y.; Liu, H.; Gu, Q.; Zhu, W. Aspergiolide A, a novel anthraquinone derivative with naphtho(1,2,3-de)chromene-2,7-dione skeleton isolated from a marine-derived fungus Aspergillus glaucus. Tetrahedron 2007, 63, 1085-1088.
15. Hawas, U.W.; Shaaban, M.; Shaaban, K.A.; Speitling, M.; Maier, A.; Kelter, G.; Fiebig, H.H.; Meiners, M.; Helmke, E.; Laatsch, H. Mansouramycins A-D, cytotoxic isoquinolinequinones from a marine streptomycete. J. Nat. Prod. 2009, 72, 2120-2124.
16. Rickards, R.W.; Rothschild, J.M.; Willis, A.C.; de Chazal, N.M.; Kirk, J.; Kirk, K.; Saliba, K.J.; Smith, G.D. Calothrixins A and B, novel pentacyclic metabolites from Calothrix cyanobacteria with potent activity against malaria parasites and human cancer cells. Tetrahedron 1999, 55, 13513.
17. Du, L.; Feng, T.; Zhao, B.; Li, D.; Cai, S.; Zhu, T.; Wang, F.; Xiao, X.; Gu, Q. Alkaloids from a deep ocean sediment-derived fungus Penicillium sp. and their antitumor activities. J. Antibiot. 2010, 63, 165-170.
18. Asolkar, R.N.; Jensen, P.R.; Kauffman, C.A.; Fenical, W. Daryamides A-C, Weakly Cytotoxic Polyketides from a Marine-Derived Actinomycete of the Genus Streptomyces Strain CNQ-085. J. Nat. Prod. 2006, 69, 1756-1759.
19. Tan, L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 2007, 68, 954-979.
20. Mayer, A.M.S.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster D.E. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 2010, 31(6), 255-265.
21. Cho, J.Y.; Williams, P.G.; Kwon, H.C.; Jensen, P.R.; Fenical, W. Lucentamycins A-D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensis. J. Nat. Prod. 2007, 70, 1321-1328.
22. Pérez, M.; Crespo, C.; Schleissner, C.; Rodríguez, P.; Zúñiga, P.; Reyes, F. Tartrolon D, a cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069. J. Nat. Prod. 2009, 72, 2192-2194.
23. Koizumi, Y.; Arai, M.; Tomoda, H.; Omura, S. Oxaline, a fungal alkaloid, arrests the cell cycle in M phase by inhibition of tubulin polymerization. Biochim. Biophys. Acta. 2004, 1693, 47-55.
24. Bringmann, G.; Gulder, T.A.; Lang, G.; Schmitt, S.; Stöhr, R.; Wiese, J.; Nagel, K.; Imhoff, J.F. Large-scale biotechnological production of the antileukemic marine natural product sorbicillactone A. Mar. Drugs 2007, 5, 23-30.
25. Kwon, H.C.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Marinomycins A-D, Antitumor-Antibiotics of a New Structure Class from a Marine Actinomycete of the Recently Discovered Genus "Marinispora". J. Am. Chem. Soc. 2006, 128, 1622-1632.
26. Lee, M.; Murphy, G. Matrix metalloproteinases at a glance. J. Cell Sci. 2004, 117, 4015-4016.
27. Gill, S.; Parks, W. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 2008, 40, 1334-1347.
28. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinase in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
29. Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the posttrial era. Nat. Rev. Cancer 2002, 2, 657-672.
30. Chen, Z.; Kim, S.K. Matrix Metalloproteinase Inhibitors (MMPIs) from Marine Natural Products: the Current Situation and Future Prospects. Mar. Drugs 2009, 7, 71-84.
31. Kim, M.M.; Kim, S.K. Chitooligosaccharides inhibit activation and expression of matrix metalloproteinase-2 in human dermal fibroblasts. FEBS Lett. 2006, 580, 2661-2666.
32. Van Ta, Q.; Kim, M.M.; Kim, S.K. Inhibitory effect of chitooligosaccharides on matrix metalloproteinase-9 in human fibrosarcoma cells (HT1080). Mar. Biotechnol. 2006, 8, 593-599.
33. Rajapakse, N.; Kim, M.M.; Mendis, E.; Huang, R.H.; Kim, S.K. Carboxylated chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via downregulation of AP-1. Biochim. Biophys. Acta 2006, 1760, 1780-1788.
34. Wang, S.B.; Cheng, Y.N.; Wang, F.S.; Sun, L.R.; Liu, C.H.; Chen, G.J.; Li, Y.H.; Ward, S.G.; Qu, X.J. Inhibition activity of sulfated polysaccharide of Sepiella maindroni ink on matrix metalloproteinase (MMP)-2. Biomed. Pharmacother. 2008, 62, 297-302.
35. Kim, M.M.; van Ta, Q.; Mendis, E.; Rajapakse, N.; Jung, W.K.; Byun, H.G.; Jeon, Y.J.; Kim, S.K. Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Sci. 2006, 79, 1436-1443.
36. Semenza, G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8(Suppl.), S62-S67.
37. Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266-276.
38. Semenza, G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 2001, 7, 345-350.
39. Kung, A.L.; Wang, S.; Klco, J.M.; Kaelin, W.G.; Livingston, D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 2000, 6, 1335-1340.
40. Mohammed, K.A.; Hossain, C.F.; Zhang, L.; Bruick, R.K.; Zhou, Y.D.; Nagle, D.G. Laurenditerpenol, a New Diterpene from the Tropical Marine Alga Laurencia intricata that Potently Inhibits HIF-1 Mediated Hypoxic Signaling in Breast Tumor Cells. J. Nat. Prod. 2004, 67, 2002-2007.
41. Liu, R.; Liu, Y.; Zhou, Y.D.; Nagle, D.G Molecular-Targeted Antitumor Agents 15: Neolamellarins from the Marine Sponge Dendrilla nigra Inhibit Hypoxia-Inducible Factor-1 (HIF-1) Activation and Secreted Vascular Endothelial Growth Factor (VEGF) Production in Breast Tumor Cells. J. Nat. Prod. 2007, 70, 1741-1745.
42. Liu, Y.; Liu, R.; Mao, S.C.; Morgan, J.B.; Jekabsons, M.B.; Zhou, Y.D.; Nagle, D.G. Molecular-Targeted Antitumor Agents. 19. Furospongolide from a Marine Lendenfeldia sp. Sponge Inhibits Hypoxia-Inducible Factor-1 Activation in Breast Tumor Cells. J. Nat. Prod. 2008, 71, 1854-1860.
43. Dai, J.; Liu, Y.; Jia, H.; Zhou, Y.D.; Nagle, D.G. Benzochromenones from the marine crinoid Comantheria rotula inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. J. Nat. Prod. 2007, 70, 1462-1466.
44. Hodges, T.W.; Hossain, C.F.; Kim, Y.P.; Zhou, Y.D.; Nagle, D.G. Molecular-Targeted Antitumor Agents: The Saururus cernuus Dineolignans Manassantin B and 4-O-Demethylmanassantin B Are Potent Inhibitors of Hypoxia-Activated HIF-1. J. Nat. Prod. 2004, 67, 767-771.
45. Nagle, D.G.; Zhou, Y.D. Marine natural products as inhibitors of hypoxic signaling in tumors. Phytochem. Rev. 2009, 8, 415-429.
46. Keutgens, A.; Robert, I.; Viatour, P.; Chariot, A. Deregulated NF-kB activity in haemological malignancies. Biochem. Pharmacol. 2006, 72, 1069-1080.
47. Baldwin, A.S. The NF-κB and I κB proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14, 649-683.
48. Folmer, F.; Jaspars, M.; Dicato, M.; Diederich, M. Marine natural products as targeted modulators of the transcription factor NF-kappa B. Biochem. Pharmacol. 2008, 75, 603-617.
49. Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.J.; Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. 2003, 42, 355-357.
50. Asolkar, R.N.; Freel, K.C.; Jensen, P.R.; Fenical, W.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, J.M. Arenamides A-C, cytotoxic NFkappaB inhibitors from the marine actinomycetes Salinispora arenicola. J. Nat. Prod. 2009, 72, 396-402.
51. Nam, S.J.; Gaudêncio, S.P.; Kauffman, C.A.; Jensen, P.R.; Kondratyuk, T.P.; Marler, L.E.; Pezzuto, J.M.; Fenical, W. Fijiolides A and B, inhibitors of TNF-alpha-induced NFkappaB activation, from a marine-derived sediment bacterium of the genus Nocardiopsis. J. Nat. Prod. 2010, 73, 1080-1086.
52. Schumacher, M.; Cerella, C.; Eifes, S.; Chateauvieux, S.; Morceau, F.; Jaspars, M.; Dicato, M.; Diederich, M. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B activation through proteasome inhibition and induces apoptotic cell death. Biochem. Pharmacol. 2010, 79, 610-622.
53. Champoux, J.J. DNA Topoisomerases: Structure, Function, and Mechanism. Ann. Rev. Biochem. 2001, 70, 369-413.
54. Dias, N.; Vezin, H.; Lansiaux, A.; Bailly, C. Topoisomerase Inhibitors of Marine Origin and Their Potential Use as Anticancer Agents. Top. Curr. Chem. 2005, 253, 89-108.
55. Bonnard, I.; Bontemps, N.; Lahmy, S.; Banaigs, B.; Combaut, G.; Francisco, C.; Colson, P.; Houssier, C.; Waring, M.J.; Bailly, C. Binding to DNA and cytotoxic evaluation of ascididemin, the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei. Anticancer Drug Des. 1995, 10, 333-346.
56. Dassonneville, L.; Wattez, N.; Baldeyrou, B.; Mahieu, C.; Lansiaux, A.; Banaigs, B.; Bonnard, I.; Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem Pharmacol. 2000, 60(4), 527-537.
57. Tardy, C.; Facompré, M.; Laine, W.; Baldeyrou, B.; García-Gravalos, D.; Francesch, A.; Mateo, C.; Pastor, A.; Jiménez, J.A.; Manzanares, I.; Cuevas, C.; Bailly, C. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg. Med. Chem. 2004, 12(7), 1697-1712.
58. Gorin, M.A.; Pan, Q. Protein kinase Cε: an oncogene and emerging tumor biomarker. Mol. Cancer 2009, 8, 9.
59. Pettit, G.R.; Herald, C.L.; Doubek, D.L.; Herald, D.L.; Arnold, E.; Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 1982, 104, 6846-6848.
60. Mutter, R.; Wills, M. Chemistry and Clinical Biology of the Bryostatins. Bioorg. Med. Chem. 2000, 8, 1841-1860.
61. Kortmansky, J.; Schwartz, G.K. Bryostatin-1: A novel PKC inhibitor in clinical development. Cancer Invest. 2003, 21, 924-936.
62. Keck, G.E.; Poudel, Y.B.; Welch, D.S.; Kraft, M.B.; Truong, A.P.; Stephens, J.C.; Kedei, N.; Lewin, N.E.; Blumberg, P.M. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters. Org. Lett. 2009, 11, 593-596.
63. Jackson, K.L.; Henderson, J.A., Phillips, A.J. The Halichondrins and E7389. Chem. Rev. 2009, 109(7), 3044-3079.
64. Okouneva, T.; Azarenko, O.; Wilson, L.; Littlefield, B.A.; Jordan, M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008, 7, 2003-2011.
65. Watanabe, J.; Natsume, T.; Kobayashi, M. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Anticancer Drugs 2007, 18, 905-911.
66. Mitsiades, C.S.; Ocio, E.M.; Pandiella, A.; Maiso, P.; Gajate, C.; Garayoa, M.; Vilanova, D.; Montero, J.; Mitsiades, N.; McMullan, C.J.; Munshi, N.C.; Hideshima, T.; Chauhan, D.; Aviles, P.; Otero, G.; Faircloth, G.; Mateos, M.V.; Richardson, P.G.; Mollinedo, F.; San-Miguel, J.F.; Anderson, K.C. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008, 68, 5216-5225.
67. Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.; Sekiya, H.; Uno, I. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg. Med. Chem. Lett. 1997, 7, 2847-2852.
68. Nicholson, B.; Lloyd, G.K.; Miller, B.R.; Palladino, M.A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S.T. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticanc. Drugs 2006, 17, 25-31.
69. Davidson, S.K.; Allen, S.W.; Lim, G.E.; Anderson, C.M.; Haygood, M.G. Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina. Appl. Environ. Microbiol. 2001, 67, 4531-4537.
70. Thakur, N.L.; Thakur, A.L. Marine Biotechnology: an overview. Ind. J. Biotechnol. 2006, 5, 263-268.
71. Nereus Pharmaceuticals homepage. Available online: http://www. nereuspharm.com/overview.shtml (accessed on 02 July 2010).
72. Schwartsmann, G.; Da Rocha, A.B.; Berlinck, R.G.; Jimeno, J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001, 2, 221-225.
73. Wang Y.; Lyu, Y.L.; Wang, J.C. Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. Proc. Natl. Acad. Sci. USA 2002, 99, 12114-12119.
74. Goulaouic, H.; Roulon, T.; Flamand, O.; Grondard, L.; Lavelle, F.; Riou, J.F. Purification and characterization of human DNA topoisomerase III alpha. Nucleic Acids Res. 1999, 27, 2443-2450.
75. Swami, M. Hypoxia: The HIF2α puzzle. Nat. Rev. Cancer 2010, 10, 603.
76. Lam, K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 2006, 9, 245-251.
77. Bull, A.T.; Ward, A.C.; Goodfellow. M. Search and discovery strategies for biotechnology: the paradigm shift. Microbiol. Mol. Biol. Rev. 2000, 64, 573-606.
78. Hanash, S.; Taguchi, A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 2010, 10, 652-660.
79. Chittiboyina, A.G.; Kumar, G.M.; Carvalho, P.B.; Liu, Y.; Zhou, Y.D.; Nagle, D.G.; Avery, M.A. Total synthesis and absolute configuration of laurenditerpenol: a HIF-1 activation inhibitor. J. Med. Chem. 2007, 50, 6299-6302.
80. Jung, M.E., Im, G.Y.J. Convergent total synthesis of the racemic HIF-1 inhibitor laurenditerpenol. Tetrahedron Lett. 2008, 49, 4962-4964.
81. Bhadury, P.; Mohammad, B.T.; Wright, P.C. The current status of natural products from marine fungi and their potential as anti-infective agents. J. Ind. Microbiol. Biotechnol. 2006, 33, 325-337.
82. Newman, D.J.; Hill, R.T. New drugs from marine microbes: the tide is turning. J. Ind. Microbiol. Biotechnol. 2006, 33, 539-544.
83. Belofsky, G.N.; Jensen, P.R.; Fenical, W. Sansalvamide: A new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Lett. 1999, 40, 2913-2916.
84. Raghukumar, C. Marine fungal biotechnology: an ecological perspective. Fungal Divers. 2008, 31, 19-35.
85. Moradali, M.F.; Mostafavi, H.; Ghods, S.; Hedjaroude, G.A. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int. Immunopharmacol. 2007, 7, 701-724.
86. Xie, S.; Xiao, J.; Xu, J. Advance in microbial ribosome engineering. Wei Sheng Wu Xue Bao. 2009, 49, 981-986.
87. Andersen, J.N.; Sathyanarayanan, S.; Di Bacco, A.; Chi, A.; Zhang, T.; Chen, A.H.; Dolinski, B.; Kraus, M.; Roberts, B.; Arthur, W.; Klinghoffer, R.A.; Gargano, D.; Li, L.; Feldman, I.; Lynch, B.; Rush, J., Hendrickson, R.C.; Blume-Jensen, P.; Paweletz, C.P. Pathway-based identification of biomarkers for targeted therapeutics: Personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med. 2010, 2, 43ra55.
88. Borkakoti, N. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Transactions 2004, 32, 17-20.